What Benefits Have Glutathione Injections Actually Shown?
1. Possible Benefit in Specific Chemotherapy Settings
Some of the better human evidence for injected glutathione comes from oncology supportive-care research rather than general wellness.
In a 1995 randomized, double-blind, placebo-controlled trial involving 50 people with advanced gastric cancer receiving cisplatin-based chemotherapy, patients assigned to glutathione experienced substantially less neurotoxicity than the placebo group. The protocol included intravenous glutathione before cisplatin and intramuscular glutathione on subsequent days.
However, a later phase 3 randomized trial evaluating glutathione during paclitaxel/carboplatin treatment did not find a reduction in chemotherapy-induced peripheral neuropathy. This suggests that any benefit may depend on the treatment regimen and clinical context rather than representing a universal effect of injectable glutathione.
2. Skin Lightening or Brightening: Evidence Is Weak for IV Use
Skin appearance is one of the most heavily promoted reasons for glutathione injections, but the evidence for IV use is weak.
A 2025 systematic review found several randomized trials of oral glutathione and studies of topical formulations, but only one placebo-controlled study of intravenous glutathione. In that IV study, the reported difference did not reach conventional statistical significance, and the review concluded that IV glutathione should not be used for skin lightening because of inadequate efficacy and safety concerns.
Evidence from oral or topical glutathione should not be assumed to apply to injections.
3. Parkinson's Disease: Early Research Has Not Proven a Clinical Benefit
Intravenous glutathione has also been studied in Parkinson's disease. A small randomized, double-blind pilot trial published in 2009 enrolled 21 participants and compared IV glutathione with placebo for four weeks.
The treatment was reported as well tolerated in that study, but it did not produce a statistically significant improvement in motor outcomes versus placebo. Because the trial was small and exploratory, it does not establish IV glutathione as an effective Parkinson's treatment.